Posted by Michael Wonder on 23 Aug 2019
Australia’s deadliest cancer has a new treatment
23 August 2019 - A powerful new combination treatment for Australia’s deadliest cancer has been approved for subsidy in a move that could dramatically extend the lifespan of lung cancer patients.
A high-cost new combination therapy for Australia’s deadliest cancer has been approved for subsidy saving lung cancer patients $15,000 every three months.
The treatment which combines high cost immunotherapy Keytruda with chemotherapy has been shown to dramatically improve five-year survival rates in non-small cell lung cancer patients from just 5% to almost 25%.
